Evidence map›Paper›PMID 41063164›Full record

ArticleBMC pulmonary medicine2025

A novel disulfidptosis-related mRNA signature predicts prognosis and therapeutic response in lung squamous cell carcinoma.

Wei Bai, Ning Jiang, Yuhan Deng, Xiaofeng Tang, Feifei Zhang, Shaorui Niu, Yuyang Yao, Yuhao Zhou, Kangming Chen, Liping Li and 2 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Wei Bai *School of Public Health, Jiangxi Medical College, Nanchang University, Nanchang330006, China.
Ning Jiang *Jiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical College, The Central Lab of The First Hospital of Nanchang, Nanchang University, North 128 Xiangshan Road, Nanchang, 330008, China.
Yuhan DengJiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical College, The Central Lab of The First Hospital of Nanchang, Nanchang University, North 128 Xiangshan Road, Nanchang, 330008, China.
Xiaofeng TangJiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical College, The Central Lab of The First Hospital of Nanchang, Nanchang University, North 128 Xiangshan Road, Nanchang, 330008, China.
Feifei ZhangJiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical College, The Central Lab of The First Hospital of Nanchang, Nanchang University, North 128 Xiangshan Road, Nanchang, 330008, China.
Shaorui NiuJiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical College, The Central Lab of The First Hospital of Nanchang, Nanchang University, North 128 Xiangshan Road, Nanchang, 330008, China.
Yuyang YaoJiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical College, The Central Lab of The First Hospital of Nanchang, Nanchang University, North 128 Xiangshan Road, Nanchang, 330008, China.
Yuhao ZhouJiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical College, The Central Lab of The First Hospital of Nanchang, Nanchang University, North 128 Xiangshan Road, Nanchang, 330008, China.
Kangming ChenJiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical College, The Central Lab of The First Hospital of Nanchang, Nanchang University, North 128 Xiangshan Road, Nanchang, 330008, China.
Liping LiSchool of Public Health, Jiangxi Medical College, Nanchang University, Nanchang330006, China.
Jun YangJiangxi Key Laboratory of Oncology, The Third Affiliated Hospital, Jiangxi Medical College, The Central Lab of The First Hospital of Nanchang, Nanchang University, North 128 Xiangshan Road, Nanchang, 330008, China. jjun.0220@163.com.
Xiao-Bin LvSchool of Public Health, Jiangxi Medical College, Nanchang University, Nanchang330006, China. nclvxiaobin@ncu.edu.cn.

Funding

Double Thousand Talents Project of Jiangxi Province jxsq2023201077National Natural Science Foundation of China 82360472Natural Science Foundation of Jiangxi Province 20232BAB20609
6 · The paper itself

Abstract

backgroundLung squamous cell carcinoma (LUSC) remains an aggressive malignancy with limited therapeutic options and poor prognosis. Recent studies have identified disulfidptosis as a novel form of metabolic stress-induced cell death, but its clinical implications in LUSC remain unexplored. This study investigates the prognostic value of disulfidptosis-related genes (DRGs) in LUSC.

methodsWe analyzed transcriptomic data from TCGA-LUSC cohort and identified DRGs through intersection with established disulfidptosis-related gene sets. A protein-protein interaction (PPI) network was constructed, and univariate Cox regression was performed to select prognostic genes. A risk score model was developed using multivariate Cox regression. The model's performance was evaluated using ROC curve and Kaplan-Meier analyses. Functional enrichment and immune microenvironment analyses were conducted to explore potential mechanisms.

resultsWe identified 9 prognostic DRGs (FHOD1, ORC5, TRIR, ALKBH1, EPS8L2, MBLAC1, MYADM, HTRA2, and SRI) that significantly correlated with patient survival. The risk score model effectively stratified patients into high- and low-risk groups (P < 0.001), with C-index values of 0.78 at 1 year and 0.75 at 3 years. High-risk patients showed enriched cytokine-cytokine receptor interactions and immunosuppressive microenvironments, while low-risk patients exhibited activated metabolic pathways. Experimental validation confirmed ORC5's oncogenic role in promoting proliferation and invasion.

conclusionWe established a novel 9-gene prognostic signature based on disulfidptosis-related genes that effectively predicts LUSC outcomes. These findings highlight the clinical relevance of disulfidptosis in LUSC and provide potential biomarkers for risk stratification and therapeutic targeting.

Indexed as

Carcinoma, Squamous CellLung NeoplasmsRNA, MessengerAgedBiomarkers, TumorDisulfidptosisFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisProtein Interaction MapsTranscriptomeTumor MicroenvironmentBiomarkers, TumorRNA, MessengerDisulfidptosisLung squamous cell carcinomaPrognostic signatureRisk stratificationTumor microenvironment AUV

Identifiers

PMID41063164
PMCPMC12505621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.